| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.34 | 1e-19 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.33 | 5e-10 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-07 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.16 | 7e-07 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.27 | 1e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.32 | 1e-06 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.31 | 5e-06 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-05 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.22 | 0.0001 |